Novo Nordisk Trades $1.17 Billion Nanexa Bet and Fresh Semaglutide Evidence Against a 25% Annual Slide

Novo Nordisk licenses PharmaShell and Hengrui drugs while publishing data to keep patients on semaglutide as shares fall 25% in 2026.

Novo Nordisk is fighting on two fronts at once. On one side, the Danish drugmaker is buying and licensing its way into the next generation of metabolic medicines. On the other, it is arming its sales force with large-scale patient data designed to keep doctors prescribing its existing franchise rather than switching to Eli Lilly's rival products.

The dual strategy emerged in a cluster of announcements spanning late September and mid-October, capped by a Friday close of EUR 33.06 that leaves the shares down 25% since the start of the year.

A licensing spree aimed at the patent cliff

The most expensive single move came through a worldwide exclusive license to PharmaShell, the drug-delivery technology owned by Sweden's Nanexa. The deal covers development rights to as many as five peptide programs targeting obesity, type 2 diabetes and other cardiometabolic conditions.

Nanexa put the total financial scope at up to EUR 1.165 billion in upfront and milestone payments. That figure breaks down into EUR 615 million tied to the upfront sum and to future development and approval milestones, plus potential royalties on eventual product sales.

The transaction speaks to a structural worry: Novo Nordisk needs delivery technologies that can carry new peptide compounds long after its flagship molecule loses exclusivity. Management is effectively stockpiling the platforms on which future product generations will be built, even as Lilly keeps the growth pressure turned up.

That logic carried over to a second deal on 29 September, when the company secured exclusive rights from Jiangsu Hengrui Pharmaceuticals to the oral candidate HRS-1596 outside China. The agreement carries a potential total value of up to USD 2.6 billion, including a USD 300 million upfront payment.

Clinical ammunition against switching

Novo Nordisk's defensive play is just as deliberate. On Tuesday the company published a retrospective analysis covering 636,525 adults with type 2 diabetes. Raising the semaglutide dose was associated with a 6% lower risk of major cardiovascular events than switching patients to tirzepatide. For prescribers, the study hands them a concrete reason to keep patients on Ozempic rather than move them across to the competition.

More support arrived later in the week. Data from the STEP-UP trial showed liver fat normalized completely in 88.5% of previously affected participants after 72 weeks on semaglutide. Then, on Wednesday, results from the OCTANE study indicated that patients who switched to the Wegovy pill lost an average of 4.1% of their body weight within three months.

Taken together, the three datasets push a single message: the value of the Novo Nordisk portfolio extends well beyond the number on the scale. That matters because global demand for obesity and diabetes treatments is expanding fast, and Lilly is pressing into the same market with its own drugs.

A 2030 roadmap that investors met with caution

The strategic frame around all of this was set at a capital markets day on 21 September, when Novo Nordisk laid out ambitions for the coming decade. The plan envisions launching more than five blockbuster products by 2030 at a broadly stable operating margin, and generating pipeline revenue above DKK 150 billion by 2035. The company was explicit that these are targets, not an official financial forecast.

Reuters reported that investors greeted the presentation skeptically. Ongoing debate about future pricing power and the approaching loss of exclusivity on the lead molecule semaglutide has kept sentiment restrained. Adding to the unease, Novo Nordisk guided for only mid-single-digit revenue growth across 2026 to 2030, raising questions about how durable the expansion story really is.

Denecimig slips, guidance holds

Not every thread is running smoothly. The US Food and Drug Administration extended its review of Denecimig, the company's hemophilia treatment, because remediation work at a manufacturing site is still outstanding. The agency did not raise any concerns about efficacy or safety.

Novo Nordisk still aims for a US launch in the first half of 2027 and reaffirmed its financial outlook for 2026. Even so, the delay has fed into the broader uncertainty reflected in the share price, which ended Friday's session at EUR 33.06 — a level that leaves the stock 25% lower year to date.